Esophageal Cancer clinical trials at UC Davis

• A Study of Experimental NGM120 Combination Therapy for Advanced Solid Tumors and Pancreatic Cancer

  open to eligible people ages 18 years and up

  Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer.

  Sacramento, California and other locations

• A Study of the Experimental Combination of Olaparib and Ramucirumab For Metastatic Gastric or Gastroesophageal Junction Cancer

  open to eligible people ages 18 years and up

  This phase I/II trial studies the side effects and best dose of olaparib when given together with ramucirumab and how well they work in treating patients with gastric or gastroesophageal junction cancer that has spread to other places in the body (metastatic), has come back (recurrent), or cannot be removed by surgery (unresectable). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ramucirumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving olaparib and ramucirumab may work better in treating patients with gastric or gastroesophageal junction cancer compared to ramucirumab and paclitaxel (a chemotherapy drug) or ramucirumab alone.

  Sacramento, California and other locations

• A Study of the Experimental Medicine INCB001158 Combined With Chemotherapy For Solid Tumor Cancers

  open to eligible people ages 18 years and up

  The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.

  Sacramento, California and other locations

• Experimental TAS-102 and Irinotecan for Gastric and Gastroesophageal Adenocarcinoma (stomach cancer)

  open to eligible people ages 18 years and up

  This is a phase Ib single-arm, open-label clinical trial determining the feasibility and efficacy of TAS-102 and irinotecan in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who are not candidates for curative treatments and who have received at least one prior line of chemotherapy with a fluoropyrimidine and platinum agent.

  Sacramento, California and other locations

• Experimental Tislelizumab With Chemotherapy For Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Cancer

  open to eligible people ages 18 years and up

  This is a randomized (1:1), double-blind, placebo-controlled, Phase 3 study designed to compare the efficacy and safety of tislelizumab or placebo plus chemotherapy as first-line (1L) therapy for locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

  Sacramento, California and other locations

Last updated: May 2, 2020